Latest News about SNY
Recent news which mentions SNY
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
October 25, 2024
From Benzinga
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
October 21, 2024
From Benzinga
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
October 21, 2024
From Motley Fool
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
October 18, 2024
From Benzinga
France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block
October 18, 2024
From Benzinga
Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R
October 15, 2024
From Benzinga
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
October 11, 2024
From Benzinga
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
October 10, 2024
From Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
From Benzinga
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
October 07, 2024
From Motley Fool
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
October 04, 2024
From Benzinga
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
October 04, 2024
From Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
From Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
From Benzinga
From Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
From Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
From Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
From Benzinga
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
September 23, 2024
From Benzinga
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
September 23, 2024
From Benzinga
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
September 20, 2024
From Benzinga
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
September 20, 2024
From Benzinga
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
From Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
From Motley Fool
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
From Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.